IL289192A - A method for treating idiopathic pulmonary fibrosis - Google Patents
A method for treating idiopathic pulmonary fibrosisInfo
- Publication number
- IL289192A IL289192A IL289192A IL28919221A IL289192A IL 289192 A IL289192 A IL 289192A IL 289192 A IL289192 A IL 289192A IL 28919221 A IL28919221 A IL 28919221A IL 289192 A IL289192 A IL 289192A
- Authority
- IL
- Israel
- Prior art keywords
- pulmonary fibrosis
- idiopathic pulmonary
- treating idiopathic
- treating
- fibrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019092675 | 2019-06-25 | ||
| PCT/CN2020/097881 WO2020259528A1 (zh) | 2019-06-25 | 2020-06-24 | 治疗特发性肺纤维化的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL289192A true IL289192A (en) | 2022-02-01 |
Family
ID=74061495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289192A IL289192A (en) | 2019-06-25 | 2021-12-21 | A method for treating idiopathic pulmonary fibrosis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12582653B2 (https=) |
| EP (1) | EP3992183A4 (https=) |
| JP (1) | JP7615061B2 (https=) |
| KR (1) | KR20220029681A (https=) |
| CN (2) | CN114026072A (https=) |
| AU (1) | AU2020305979B2 (https=) |
| BR (1) | BR112021026214A2 (https=) |
| CA (1) | CA3144113A1 (https=) |
| IL (1) | IL289192A (https=) |
| TW (1) | TWI804743B (https=) |
| WO (1) | WO2020259528A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023539276A (ja) * | 2020-08-31 | 2023-09-13 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用 |
| CA3209240A1 (en) * | 2021-02-22 | 2022-08-25 | Samuel D. Waksal | Rock2 inhibitor for the treatment of viral infection |
| NO346587B1 (en) * | 2021-06-02 | 2022-10-17 | Axichem Ab | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis |
| TW202327608A (zh) * | 2021-09-17 | 2023-07-16 | 北京泰德製藥股份有限公司 | 治療病毒感染的方法 |
| IL311447A (en) * | 2021-09-18 | 2024-05-01 | Beijing Tide Pharmaceutical Co Ltd | A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof |
| KR20240095429A (ko) * | 2021-11-16 | 2024-06-25 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Rock2 억제제의 나노결정 제제 및 이의 제조방법 |
| WO2023134688A1 (zh) * | 2022-01-13 | 2023-07-20 | 武汉朗来科技发展有限公司 | 一种rock抑制剂的盐及盐的晶型、组合物和药物用途 |
| EP4591863A1 (en) * | 2022-10-13 | 2025-07-30 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating pneumoconiosis |
| WO2025017499A1 (en) | 2023-07-17 | 2025-01-23 | Graviton Bioscience Bv | Formulations and uses of rock2 inhibitors for als |
| IL325831A (en) | 2023-07-17 | 2026-03-01 | Graviton Bioscience Bv | ROCK2 inhibitor formulations for central nervous system disorders |
| WO2025069008A1 (en) | 2023-09-28 | 2025-04-03 | Graviton Bioscience Bv | Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors |
| WO2025069009A1 (en) | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138335A1 (en) * | 2015-02-27 | 2016-09-01 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
| AR110401A1 (es) | 2016-12-21 | 2019-03-27 | Chiesi Farm Spa | Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa |
| CN110582489B (zh) * | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| WO2019000682A1 (zh) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
-
2020
- 2020-06-24 CA CA3144113A patent/CA3144113A1/en active Pending
- 2020-06-24 TW TW109121568A patent/TWI804743B/zh active
- 2020-06-24 BR BR112021026214A patent/BR112021026214A2/pt unknown
- 2020-06-24 CN CN202080045478.XA patent/CN114026072A/zh active Pending
- 2020-06-24 JP JP2021576479A patent/JP7615061B2/ja active Active
- 2020-06-24 US US17/621,719 patent/US12582653B2/en active Active
- 2020-06-24 WO PCT/CN2020/097881 patent/WO2020259528A1/zh not_active Ceased
- 2020-06-24 CN CN202510159677.8A patent/CN119868365A/zh active Pending
- 2020-06-24 EP EP20833444.1A patent/EP3992183A4/en active Pending
- 2020-06-24 AU AU2020305979A patent/AU2020305979B2/en active Active
- 2020-06-24 KR KR1020227002368A patent/KR20220029681A/ko active Pending
-
2021
- 2021-12-21 IL IL289192A patent/IL289192A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3992183A1 (en) | 2022-05-04 |
| US20220233538A1 (en) | 2022-07-28 |
| EP3992183A4 (en) | 2023-06-21 |
| TW202114679A (zh) | 2021-04-16 |
| KR20220029681A (ko) | 2022-03-08 |
| US12582653B2 (en) | 2026-03-24 |
| AU2020305979A1 (en) | 2022-02-17 |
| JP2022539329A (ja) | 2022-09-08 |
| JP7615061B2 (ja) | 2025-01-16 |
| CN114026072A (zh) | 2022-02-08 |
| AU2020305979B2 (en) | 2026-04-23 |
| WO2020259528A1 (zh) | 2020-12-30 |
| CA3144113A1 (en) | 2020-12-30 |
| CN119868365A (zh) | 2025-04-25 |
| TWI804743B (zh) | 2023-06-11 |
| BR112021026214A2 (pt) | 2022-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289192A (en) | A method for treating idiopathic pulmonary fibrosis | |
| GB201907244D0 (en) | Method | |
| GB201909562D0 (en) | Method | |
| GB201913997D0 (en) | Method | |
| EP3116543A4 (en) | Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf) | |
| GB201917742D0 (en) | Method | |
| GB201910759D0 (en) | Method | |
| GB201900940D0 (en) | Method | |
| GB201900647D0 (en) | Method | |
| GB201917060D0 (en) | Method | |
| IL289648A (en) | method | |
| EP3139912A4 (en) | Method of treating idiopathic pulmonary fibrosis | |
| GB201917824D0 (en) | Method | |
| GB201917638D0 (en) | Method | |
| GB201913970D0 (en) | Method | |
| GB201910404D0 (en) | Method | |
| GB201906768D0 (en) | Method | |
| GB201901532D0 (en) | Method | |
| HK40045282A (en) | Methods and compositions for treating idiopathic pulmonary fibrosis | |
| GB201914595D0 (en) | Cleaning method | |
| GB201908508D0 (en) | Refurbishment method | |
| GB202007297D0 (en) | Method | |
| GB2587925B (en) | Method | |
| GB201918290D0 (en) | Method | |
| GB201917806D0 (en) | Method |